Form 8-K

8-K — Cigna Group

Accession: 0001140361-26-017971

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0001739940

SIC: 6324 (HOSPITAL & MEDICAL SERVICE PLANS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ef20071317_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ef20071317_ex99-1.htm)

GRAPHIC (image0.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20071317_8k.htm · Sequence: 1

false0001739940NYSE00017399402026-04-302026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2026

The Cigna Group

(Exact name of registrant as specified in its charter)

Delaware

001-38769

82-4991898

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

900 Cottage Grove Road

Bloomfield, Connecticut 06002

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (860) 226-6000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.01

New York Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule

12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On April 30, 2026, The Cigna Group issued a press release announcing results for the three months ended March 31, 2026. The press release is furnished as

Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or

incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press release dated April 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned hereunto duly authorized.

THE CIGNA GROUP

Date: April 30, 2026

By:

/s/ Ann M. Dennison

Ann M. Dennison

Executive Vice President and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20071317_ex99-1.htm · Sequence: 2

Exhibit 99.1

Press Release

INVESTOR RELATIONS CONTACT:

Ralph Giacobbe

860-787-7968

Ralph.Giacobbe@TheCignaGroup.com

MEDIA CONTACT:

Justine Sessions

860-810-6523

Justine.Sessions@Evernorth.com

The Cigna Group Reports Strong First Quarter 2026 Results, Raises 2026 Outlook

•

Total revenues for the first quarter 2026 increased 5% to $68.5 billion

•

Shareholders’ net income for the first quarter 2026 was $1.7 billion, or $6.26 per share

•

Adjusted income from operations1 for the first quarter 2026 was $2.1 billion, or $7.79 per share

•

2026 outlook2 for adjusted income from operations1,2 increased to at least $30.35 per share2

BLOOMFIELD, CT, April 30, 2026 – Global health company The Cigna Group (NYSE: CI) today reported first quarter 2026 results, reflecting growth across its diversified portfolio of businesses.

“We continue to improve how people experience health care, leveraging innovation and technology to make it more personalized, more transparent and easier to navigate,”

said David M. Cordani, chairman and CEO of The Cigna Group. “Our strong first quarter results were driven by disciplined execution, deliberate portfolio shaping and a

continued focus on targeted innovation.”

Shareholders’ net income for first quarter 2026 was $1.7 billion, or $6.26 per share compared to $1.3 billion, or $4.85 per share, for first quarter 2025, reflecting growth across the enterprise.

The Cigna Group's adjusted income from operations1 for first quarter 2026 was $2.1 billion, or $7.79

per share, compared with $1.8 billion, or $6.74 per share, for first quarter 2025.

A reconciliation of shareholders’ net income to adjusted income from operations1 is provided on the following page and on Exhibit 1

of this earnings release.

CONSOLIDATED HIGHLIGHTS

The following table includes highlights of results and reconciliations

of total revenues to adjusted revenues3 and shareholders’ net income to adjusted income from operations1:

Consolidated Financial Results (unaudited, dollars in millions):

Three Months Ended

March 31,

December 31,

2026

2025

Total Revenues

68,494

65,502

72,472

Net Investment Results from Equity Method Investments3

(50

)

Adjusted Revenues3

68,517

65,452

72,495

Consolidated Earnings, net of taxes

Shareholders’ Net Income

1,654

1,323

1,234

Net Investment (Gains) Losses1

(233

)

(48

)

104

Amortization of Acquired Intangible Assets1

315

336

327

Special Items1

322

229

483

Adjusted Income from Operations1

2,058

1,840

2,148

Shareholders’ Net Income, per share

6.26

4.85

4.64

Adjusted Income from Operations1, per share

7.79

6.74

8.08

•

Total revenues for first quarter 2026 increased 5% relative to first quarter 2025, primarily driven by growth in Evernorth Health Services, partially offset by the impact of the HCSC transaction4.

•

Adjusted income from operations1 for first quarter 2026 increased 12% relative to first quarter 2025, driven by higher contributions primarily from Cigna Healthcare, as well as Evernorth Health Services.

•

The SG&A expense ratio5 and adjusted SG&A expense ratio5 were 5.4% and 4.8% for

first quarter 2026, compared to 6.4% and 5.8%, respectively, in first quarter 2025, reflecting business mix shift as well as improved operating efficiency.

•

The debt-to-capitalization ratio was 42.3% at March 31, 2026, compared to 43.0% at December 31, 2025.

CUSTOMER RELATIONSHIPS

The following table summarizes The Cigna Group’s medical customers and overall customer relationships:

Customer Relationships (in thousands):

As of the Periods Ended

March 31,

December 31,

2026

2025

Total Pharmacy Customers6

121,020

122,283

123,603

U.S. Healthcare

16,623

16,364

16,423

International Health

1,711

1,679

1,695

Total Medical Customers6

18,334

18,043

18,118

Behavioral Care

27,558

23,416

28,269

Dental

18,558

18,466

18,438

Total Customer Relationships6

185,470

182,208

188,428

•

Total customer relationships6 at March 31, 2026 decreased 2% from December 31, 2025 to 185.5 million.

•

Total pharmacy customers6 at March 31, 2026 decreased 2% from December 31, 2025 to 121.0 million, reflecting expected

client transitions and lower membership from health plan clients.

•

Total medical customers6 at March 31, 2026 increased 1% from December 31, 2025 to 18.3 million reflecting growth in

Middle, Select, and International markets, partially offset by lower membership in National Accounts.

HIGHLIGHTS OF SEGMENT RESULTS

See Exhibit 1 for a reconciliation of adjusted income from operations1 to shareholders’ net income.

Evernorth Health Services

This segment includes the Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated

health solutions and capabilities to enable the health care system to work better and help people live healthier lives.

Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy

network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases,

specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.

Financial Results (dollars in millions):

Three Months Ended

March 31,

December 31,

2026

2025

Total Adjusted Revenues

Pharmacy Benefit Services

33,002

29,742

36,339

Specialty and Care Services

25,440

23,939

26,717

Adjusted Revenues3

58,442

53,681

63,056

Adjusted Income from Operations, Pre-Tax

Pharmacy Benefit Services

394

544

1,154

Specialty and Care Services

1,072

890

1,034

Adjusted Income from Operations, Pre-Tax1

1,466

1,434

2,188

Margin, Pre-Tax7

2.5

2.7

3.5

•

Evernorth Health Services first quarter 2026

adjusted revenues3 and adjusted income from operations, pre-tax1, increased 9% and 2%, respectively, relative to first quarter 2025.

•

For Pharmacy Benefit Services first quarter 2026 relative to first quarter 2025:

◦

Adjusted revenues3 increased 11% primarily due to drug mix.

◦

Adjusted income from operations, pre-tax1, decreased 28%, primarily reflecting expected lower contributions from large client relationships, consistent with prior commentary.

•

For Specialty and Care Services first quarter 2026 relative to first quarter 2025:

◦

Adjusted revenues3 increased 6% reflecting strong specialty volume growth.

◦

Adjusted income from operations, pre-tax1, increased 20% primarily reflecting strong organic growth in

specialty businesses, including increased generic and biosimilar adoption that continues to lower costs for clients and patients.

Cigna Healthcare

This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and

customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as individual and family plan customers. International Health provides health care solutions in our international

markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare included the Medicare and related businesses until the divestiture of such businesses to Health Care Services

Corporation (“HCSC”)4 on March 19, 2025.

Financial Results (dollars in millions):

Three Months Ended

March 31,

December 31,

2026

2025

Adjusted Revenues3,8

11,477

14,482

11,172

Adjusted Income from Operations, Pre-Tax1

1,514

1,287

734

Margin, Pre-Tax7

13.2

8.9

6.6

•

First quarter 2026 adjusted revenues3,8 decreased 21% relative to first

quarter 2025, primarily reflecting the impact of the HCSC transaction4,8. Excluding the impact of the HCSC transaction4,8, first quarter 2026 adjusted revenues3,8 increased 8% relative to first quarter 2025, primarily driven by premium rate increases to cover expected increases

in medical costs.

•

First quarter 2026 adjusted income from operations, pre-tax1, increased 18% relative to first quarter 2025, driven by improved margins in U.S. Healthcare across both U.S. Employer and Individual and Family Plan

businesses.

•

The Cigna Healthcare MCR5 was 79.8% for first

quarter 2026, compared to 82.2% for first quarter 2025, primarily reflecting the impact of the HCSC transaction4.

•

Cigna Healthcare net medical costs payable9 was $4.78 billion at March 31, 2026, $4.09 billion at December 31, 2025, and $4.37 billion at March 31, 2025. The sequential increase reflects typical stop loss seasonality. Favorable prior year reserve development on a gross pre-tax basis was $188 million and $222 million for the three months ended March 31, 2026 and 2025, respectively.

Corporate and Other Operations

Corporate reflects interest expense, amounts not

allocated to operating segments and includes intersegment eliminations. Other Operations is comprised of Corporate Owned Life Insurance (“COLI”), the Company’s run-off operations and other non-strategic businesses.

Financial Results (dollars in millions):

Three Months Ended

March 31,

December 31,

2026

2025

Adjusted (Loss) from Operations, Pre-Tax1

(377

)

(411

)

(373

)

2026 OUTLOOK2

The Cigna Group’s outlook for full year 2026 consolidated adjusted income from operations1,2

is at least $30.35 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2026 dividends.

(dollars in millions, except where noted and per share amounts)

2026 Consolidated Metrics

Projection for Full Year Ending

December 31, 2026

Change from Prior Projection

Adjusted Income from Operations, per share1,2

at least $30.35

+$0.10

Evernorth Adjusted Income from Operations, Pre-Tax1,2

at least $6,900

Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2

at least $4,525

+$25

Cigna Healthcare Medical Care Ratio2,4

83.7% to 84.7%

The foregoing statements represent the Company’s current estimates of The Cigna Group's 2026 consolidated and segment adjusted income from operations1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of

factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.

This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group’s website in the Investor Relations

section (https://investors.thecignagroup.com/overview/default.aspx). Management will be hosting a conference call to review first quarter 2026 results and discuss full year 2026 outlook beginning today at 8:30 a.m. ET. A link to the conference call is available in the Investor

Relations section of The Cigna Group's website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx.

The call-in numbers for the conference call are as follows:

Live Call

(888) 566-1889 (Domestic)

(773) 799-3989

(International)

Passcode: 04302026

Replay

(866) 405-7290

(Domestic)

(203) 369-0603 (International)

It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.

About The Cigna Group

The Cigna Group (NYSE: CI) is a global health company committed to creating a better

future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services

marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has over 185 million customer relationships around the world. Learn

more at thecignagroup.com.

Notes:

Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the

underlying results of operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’ net income

(or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna

Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative

of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.

Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income. See Exhibit 1 for a

reconciliation of consolidated adjusted income from operations to shareholders’ net income.

Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income, on a forward-looking basis because it is unable to predict,

without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond The Cigna

Group’s control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

The Company’s outlook excludes the

potential effects of any other business combinations that may occur after the date of this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated 2026 dividends.

The timing and actual number of shares repurchased will depend on a variety of factors, including price,

general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including

through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.

Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total

revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are

matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these

items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for

the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to total revenues.

On March 19, 2025, the company completed the sale (the “HCSC transaction”) of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and

Other Supplemental Benefits, and CareAllies businesses to Health Care Services Corporation (“HCSC”).

Operating ratios are defined as follows:

•

The Cigna Healthcare medical care ratio (“MCR”) represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through

guaranteed cost or experience-rated funding arrangements. Changes in percentages may be expressed in basis points ("bps").

•

SG&A expense ratio on a GAAP basis for the first quarter 2026 represents enterprise selling, general and administrative expenses of $3,722 million as a percentage of total revenue

of $68.5 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the first

quarter 2025 represents enterprise selling, general and administrative expenses of $4,213

million as a percentage of total revenue of $65.5 billion at a consolidated level.

•

Adjusted SG&A expense ratio for the first quarter 2026 represents enterprise selling, general and administrative expenses of $3,321 million excluding special items of $401 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the first quarter 2025 represents enterprise selling, general and administrative expenses of $3,799 million excluding special items of $414 million as a percentage of adjusted revenue at a consolidated level.

Customer relationships are defined as follows:

•

Total medical customers includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy, managed care

arrangement, or administrative services agreement issued by Cigna Healthcare; (ii) have access to Cigna Healthcare's provider network for covered services under their medical plan; or (iii) have medical claims that are administered by

Cigna Healthcare.

Margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.

The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include the Company’s

share of the joint ventures’ earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.

Set forth below is a table that presents the impact of the HCSC transaction on Cigna Healthcare Adjusted

Revenues for the periods presented. Management believes that the presentation of this measure is useful to investors because it permits a comparison of the Company’s go-forward business across periods.

Financial Results (dollars in millions):

Three Months Ended

March 31,

December 31,

2026

2025

Cigna Healthcare Adjusted Revenues3

11,477

14,482

11,172

Less: U.S. Healthcare - divested businesses revenues

—

3,850

—

Cigna Healthcare Adjusted Revenues3 excluding U.S. Healthcare - divested businesses

revenues

11,477

10,632

11,172

Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other

recoverables. The gross medical costs payable balance was $4.92 billion as of March 31, 2026,

$4.24 billion as of December 31, 2025, and $4.51 billion as of March 31, 2025.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may

include, among others, statements concerning our projected outlook for 2026 (including adjusted

revenues; adjusted income from operations, including on a per share, and segment basis; adjusted SG&A expense ratio; adjusted effective tax rate; cash flow from operations; capital expenditures; shareholder dividends; weighted average shares

outstanding; medical care ratio; and total medical customers); future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational

initiatives, including our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; economic, regulatory or competitive environments; capital deployment plans and

amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance.

You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning,

although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed

or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or

result in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and

rapidly changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to

maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates

related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in

connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate

in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and

data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our

information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning;

dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our

multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to

expectations which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on

employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the

future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of

www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions

that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

THE CIGNA GROUP

Exhibit 1

COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)

Three Months Ended

Three Months

Ended

March 31,

December 31,

(Dollars in millions, except per share amounts)

2026

2025

REVENUES

Pharmacy revenues

54,037

48,633

58,336

Premiums

9,812

12,736

9,288

Fees and other revenues

4,443

3,895

4,509

Net investment income

202

238

339

Total revenues

68,494

65,502

72,472

Net investment results from certain equity method investments

(50

)

Adjusted revenues (1)

68,517

65,452

72,495

Shareholders' net income

1,654

1,323

1,234

Pre-tax adjusted income (loss) from operations by segment

Evernorth Health Services

1,466

1,434

2,188

Cigna Healthcare

1,514

1,287

734

Corporate and Other Operations

(377

)

(411

)

(373

)

Adjusted income tax expense

(545

)

(470

)

(401

)

Consolidated after-tax adjusted income from operations

2,058

1,840

2,148

Weighted average shares (in thousands)

264,017

272,953

265,699

Common shares outstanding (in thousands)

264,498

269,773

263,464

SHAREHOLDERS' EQUITY at March 31,

42,210

40,226

SHAREHOLDERS' EQUITY PER SHARE at March 31,

159.59

149.11

Three Months Ended

March 31,

Three Months

Ended

December 31,

2026

2025

(Dollars in millions, except per share amounts)

Pre-tax

After-tax

Pre-tax

After-tax

Pre-tax

After-tax

SHAREHOLDERS' NET INCOME

Shareholders' net income

1,654

1,323

1,234

Adjustments to reconcile adjusted income from operations

Net investment (gains) losses (2)

(235

)

(233

)

(48

)

(48

)

123

104

Amortization of acquired intangible assets

390

315

422

336

463

327

Special Items

Strategic optimization program

380

290

215

163

183

136

Integration and transaction-related costs

216

164

Deferred tax expenses, net

—

374

(Gain) loss on sale of businesses

—

)

(41

)

(115

)

(48

)

(Benefits) associated with litigation matters

(11

)

—

Adjusted income from operations (3)

2,058

1,840

2,148

DILUTED EARNINGS PER SHARE

Shareholders' net income

6.26

4.85

4.64

Adjustments to reconcile to adjusted income from operations

Net investment (gains) losses (2)

(0.89

)

(0.88

)

(0.18

)

(0.18

)

0.46

0.39

Amortization of acquired intangible assets

1.48

1.19

1.54

1.23

1.74

1.23

Special Items

Strategic optimization program

1.44

1.10

0.79

0.60

0.69

0.51

Integration and transaction-related costs

0.13

0.10

0.79

0.60

0.11

0.08

Deferred tax expenses, net

—

0.06

—

0.06

—

1.41

(Gain) loss on sale of businesses

—

(0.01

)

(0.15

)

(0.42

)

0.25

(0.18

)

(Benefits) associated with litigation matters

(0.04

)

(0.03

)

—

Adjusted income from operations (3)

7.79

6.74

8.08

(1) Adjusted revenues is defined as total revenues excluding the following

adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative

of past or future underlying performance of our businesses.

(2) Includes Net investment gains/losses as presented in our Consolidated

Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our

Consolidated Statements of Income.

(3) Adjusted income (loss) from operations is defined as shareholders’ net

income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net investment gains/losses, amortization of acquired intangible assets and

special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.

GRAPHIC

Filename: image0.jpg · Sequence: 6

Binary file (362483 bytes)

Download image0.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Entity File Number

001-38769

Entity Registrant Name

The Cigna Group

Entity Central Index Key

0001739940

Entity Incorporation, State or Country Code

Entity Tax Identification Number

82-4991898

Entity Address, Address Line One

900 Cottage Grove Road

Entity Address, City or Town

Bloomfield

Entity Address, State or Province

Entity Address, Postal Zip Code

06002

City Area Code

860

Local Phone Number

226-6000

Title of 12(b) Security

Common Stock, Par Value $0.01

Trading Symbol

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration